[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369127-105":59,"doc-detail-369127-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-analysis-of-helical-tomotherapy-stereotactic-body-radiotherapy-in-multiple-primary-or-second-primary-lung-cancers","Prognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers","","Purpose evaluates the safety and efficacy of Helical Tomotherapy stereotactic body radiotherapy (HT-SBRT) for multiple primary lung cancers (MPLCs) and second primary lung cancer (SPLC). Methods include 106 MPLCs/SPLC patients (T1-3N0M0) receiving HT-SBRT from January 2010 to September 2023, using competing-risk analysis for local recurrence (LR) and Kaplan-Meier with log-rank tests for cancer-specific survival (CSS) and progression-free survival (PFS). Results show adjusted LR rates, CSS/PFS outcomes, and low grade-3 toxicity. Conclusions indicate HT-SBRT may be safe and effective, pending prospective confirmation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-analysis-of-helical-tomotherapy-stereotactic-body-radiotherapy-in-multiple-primary-or-second-primary-lung-cancers/369127/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-analysis-of-helical-tomotherapy-stereotactic-body-radiotherapy-in-multiple-primary-or-second-primary-lung-cancers/369127.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patients were included in the HT-SBRT prognostic analysis?","Question",{"text":112,"@type":113},"From January 2010 to September 2023, 106 patients with multiple primary lung cancers (MPLCs) and second primary lung cancer (SPLC) (T1-3N0M0) underwent HT-SBRT.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were local recurrence, CSS, and PFS analyzed?",{"text":117,"@type":113},"Local recurrence (LR) was estimated using a competing risk approach and compared with Gray’s test. CSS and PFS were assessed using Kaplan-Meier analysis and log-rank tests.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key efficacy and safety findings?",{"text":121,"@type":113},"Adjusted LR rates were reported for all lesions and subgroups, along with CSS and PFS rates at 2, 4, and 10 years. Grade 3 acute radiation pneumonitis occurred in 0.9% of patients, and no severe (grade 4–5) toxicities were reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369127,1790195100,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Ma etal. BMC Cancer (2025) 25:118 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-13540-2](https://doi.org/10.1186/s12885-025-13540-2)  \nRESEARCH Open Access  \nPrognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers  \nJintao Ma 1, Xiaohong Xu 1, Wenhan Huang 1, Yong Hu 1, Gang Chen 1 and Jian He 1*  \nAbstract  \nPurpose To evaluate the safety and efficacy of Helical Tomotherapy stereotactic body radiotherapy (HT-SBRT) in treating multiple primary lung cancers (MPLCs) and second primary lung cancer (SPLC) .  \nMethods From January 2010 to September 2023, 106 MPLCs and SPLC (T1-3N0M0) underwent HT-SBRT. The cumulative incidence for local recurrence (LR) was calculated using the competing risk approach and compared using Gray’s test. Cancer-specific survival (CSS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and log-rank tests.  \nResults After adjusting for competing risks, the LR rates for all lesions (n = 150) was 15. 3%, with 2-and 4-year rates of 7. 5% and 11.4% . For second primary lung nodules post-surgery, the cumulative incidence of LR was 16. 1%, with 2-and 4-year rates of 6 . 9% and 8. 7% . In MPLCs treated with HT-SBRT, the cumulative incidence of LR was 14. 3%, with 2-and 4-year rates of 8 . 2% and 14. 3% . In patients with MPLCs treated with HT-SBRT (n = 27), the CSS rates at 2, 4, and 10 years were 90. 5%, 78. 6%, and 53. 6%, respectively, and the PFS rates were 59 . 5%, 32 . 8%, and 24. 6% . In patients with SPLC who received HT-SBRT after surgery (n = 79), the CSS rates at 2, 4, and 10 years were 90. 9%, 81 . 7%, and 61. 0%, respectively, while the PFS rates were 75.4%, 64 .4%, and 58. 5% . Additionally, 0. 9% of patients experienced grade 3 acute radiation pneumonitis, and no severe (grade 4–5) toxicities were reported.  \nConclusions HT-SBRT may be a safe and effective treatment for MPLCs and SPLC, though prospective studies are needed to confirm its efficacy.  \nKeywords Multiple primary lung cancer, Stereotactic body radiotherapy, Local recurrence, Survival, Toxicity  \n*Correspondence: Jian He[hejian62@163.com](hejian62@163.com)  \n1Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nIntroduction  \nWith the widespread use of low-dose computed tomography (CT) screening, advances in cancer treatment, and increased life expectancy, the incidence of multiple primary lung cancers (MPLCs) is rising annually, with approximately 10% of lung cancer patients potentially having a second primary lung cancer (SPLC) [1]. Martini and Melamed [2] first established criteria for distinguishing MPLCs from pulmonary metastases. MPLCs are defined as two or more distinct primary lung cancers occurring either simultaneously or sequentially within the same individual, potentially exhibiting the same or different h","cbCaimokIYtMqAqL","https://ap.wps.com/l/cbCaimokIYtMqAqL","pdf",1369453,"English","# Introduction\n## Disease background and diagnostic criteria\n## Treatment options and rationale for SBRT\n## Prognostic factors and knowledge gap\n## Study approach and prior evidence","[{\"question\":\"What patients were included in the HT-SBRT prognostic analysis?\",\"answer\":\"From January 2010 to September 2023, 106 patients with multiple primary lung cancers (MPLCs) and second primary lung cancer (SPLC) (T1-3N0M0) underwent HT-SBRT.\"},{\"question\":\"How were local recurrence, CSS, and PFS analyzed?\",\"answer\":\"Local recurrence (LR) was estimated using a competing risk approach and compared with Gray’s test. CSS and PFS were assessed using Kaplan-Meier analysis and log-rank tests.\"},{\"question\":\"What were the key efficacy and safety findings?\",\"answer\":\"Adjusted LR rates were reported for all lesions and subgroups, along with CSS and PFS rates at 2, 4, and 10 years. Grade 3 acute radiation pneumonitis occurred in 0.9% of patients, and no severe (grade 4–5) toxicities were reported.\"}]","Prognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers | PDF",1790180872,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/778acafe7a6a1774f0992474dfe0bc1b.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d4ba3e347493570cd4a2b9c4e35f6cd.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9e07b1abe236d1fae646efea4b37fde.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc81611a280b6989c60ef07abb863f6b.webp",980,1306]